Neema Navai, MD, MHCM
Department of Urology, Division of Surgery
About Dr. Neema Navai
I am Professor and Chair of the Department of Urology at The University of Texas MD Anderson Cancer Center, where I lead with a focus on servant leadership and team empowerment. I oversee a dynamic and innovative program dedicated to excellence in patient care, research discovery, and education.
Our department advances hyper-specialized, patient-centered care delivered by a world-class team of experts and dedicated professionals. We are accelerating progress in urologic oncology through transformative research and are deeply committed to shaping the next generation of leaders through best-in-class fellowship training, mentorship, and academic excellence.
In my enterprise role as Special Advisor to the Chief Medical Executives (CME) for Care Development, I drive strategic and operational transformation across MD Anderson. In dyad partnership with the VP of Innovation, I lead efforts to implement digital health platforms and care redesign initiatives that align with clinical leadership and organizational strategy. My focus is on building high-functioning, cross-disciplinary teams that connect operational, clinical, and innovation leaders to expand our impact and meet the needs of more patients.
I have also served on multiple institutional governance committees in patient care informatics and previously led Ambulatory Operations as Medical Director of the Genitourinary Center. My leadership emphasizes high reliability, patient safety, and systems-level excellence, always in service of MD Anderson’s mission to end cancer.
As a clinician and academic, I maintain an active practice focused on bladder cancer, with expertise in robotic surgery and complex urinary reconstruction. I am deeply committed to patient-centered care—guiding patients with empathy, honoring their values, and striving to minimize the quality-of-life impact of major surgical interventions while maintaining outstanding oncologic outcomes.
Present Title & Affiliation
Dual/Joint/Adjunct Appointment
Chair, Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Professor, Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Deputy Chair, Urology, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor, Urology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2025 | Harvard University, Boston, Massachusetts, US, Masters in Healthcare Management (MHCM) |
| 2004 | Northwestern University Feinberg School of Medicine, Chicago, Illinois, US, MD |
| 2000 | University of Michigan, Ann Arbor, Michigan, US, BS in Cellular and Molecular Biology |
Postgraduate Training
| 2010-2013 | Clinical Specialist, Fellowship, Urologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2009-2010 | Chief Urology Resident, Urology, Northwestern University, Chicago, Illinois |
| 2006-2009 | Urology Resident, Urology, Northwestern University, Chicago, Illinois |
| 2005-2006 | Clinical Residency, General Surgery, Northwestern University, Chicago, Illinois |
| 2004-2005 | Clinical Internship, General Surgery, Northwestern University, Chicago, Illinois |
Licenses & Certifications
| 2021 | Florida Telehealth Verification |
| 2015 | American Board of Urology |
Experience & Service
Administrative Appointments/Responsibilities
Chair, Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2025 - Present
Special Advisor to Chief Medical Executive, Strategy & Functional Integration (Office of the Chief Medical Executive), The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - Present
Strategic Decision Owner and Co-Chair Digital Health and Virtual Care, Office of the CME, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - Present
Deputy Chair, Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - Present
Director Bladder Cancer Robotics, Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - Present
Other Professional Positions
Member - 49 States Working Group, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present
Team Lead, Concierge Services and Virtual Options - EC Transformation, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present
OneConnect: Superuser, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - Present
EPIC Subject matter expert: GU Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - Present
Intramural Institutional Committee Activities
Project leader - upstream, Capacity Management (enterprise), The University of Texas MD Anderson Cancer Center, 2023 - Present
Co-Chair, Ambulatory Operations Informatics, The University of Texas MD Anderson Cancer Center, 2022 - Present
Extramural Institutional Committee Activities
Member, Executive Billing and Compliance Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present
Member, AMA E/M Change Sub Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present
Chair, Virtual Care and Engagement, The University of Texas MD Anderson Cancer Center, 2020 - Present
Chair, Preoperative Informatics, The University of Texas MD Anderson Cancer Center, 2019 - Present
Alternate, Division of Surgery Quality Officer, The University of Texas MD Anderson Cancer Center, 2019 - Present
Member, EHR Officer, The University of Texas MD Anderson Cancer Center, 2018 - Present
Member, Medical Records Committee, The University of Texas MD Anderson Cancer Center, 2018 - Present
Alternate, OR committee, The University of Texas MD Anderson Cancer Center, 2018 - Present
Member, Ambulatory Informatics Committee, The University of Texas MD Anderson Cancer Center, 2016 - Present
Member, Division of Surgery EPIC Committee, The University of Texas MD Anderson Cancer Center, 2016 - Present
Member, Data Services Steering Team, The University of Texas MD Anderson Cancer Center, 2016 - Present
Editorial Activities
Editorial Review Board, Annals of Surgical Oncology, 2016 - Present
Honors & Awards
| 2024 - Present | Top 10% Provider Nationally for Delivery of Care, CGCAHPS |
| 2014 | MD Anderson Research-Related Patient Care Clinical Charges Funding, The University of Texas MD Anderson Cancer Center |
| 2013 - 2014 | NIH Bladder Cancer SPORE Career Development Award, The University of Texas MD Anderson Cancer Center |
| 2012 | Best Poster: Bladder Cancer Basic Research III, AUA |
| 2012 | Trainee Excellence Award, The University of Texas MD Anderson Cancer Center |
| 2010 | SUO December Meeting Fellow/Resident Poster Award, SUO |
| 2010 | Leander W. Riba Award, Northwestern University |
| 2009 | Huggins Essay Contest, Chicago Urological Society |
| 2009 | Bipin Bhayani Resident Research Awards, Northwestern University |
| 2008 | Bipin Bhayani Resident Research Awards, Northwestern University |
| 2007 - 2008 | Gerald P. Murphy Memorial Luncheon Scholar, AUA |
| 2007 | Bipin Bhayani Resident Research Awards, Northwestern University |
| 2007 | Society of Urologic Prosthetic Surgeons/Sexual Medicine Society of North America, SUPS/SMSNA |
| 2006 | Huggins Essay Contest, Chicago Urological Society |
| 2003 | Alpha Omega Alpha Honor Society, Northwestern Medical School |
| 2000 | Class Honors, University of Michigan |
Professional Memberships
Selected Presentations & Talks
Regional Presentations
- 2025. Pfizer Inc. Invited. 21st Oncology Updates Advances and Controversies. Steamboat Springs, CO, US.
- 2024. Management of node positive Disease. Panelist. SUO Bladder Cancer Course. Dallas, TX, US.
- 2024. Introduction of the Von Eschenbach Lecturer. Invited. UT 2nd Annual Christopher G. Wood Advances in Urologic Oncology Symposium. Austin, TX, US.
- 2023. Session II (Bladder Ca Localized). Conference. UT Christopher G. Wood Advances In Urologic Oncology Symposium. Austin, TX, US.
National Presentations
- 2025. Bladder Procedures. Panelist. American Urological Association. Las Vegas, Nevada, US.
- . Conference. Aspen Urological Conference. Apsen, CO, US.
- 2024. Surgical Management of Clinically Node Positive Bladder Cancer. Panelist. Bladder Cancer Course. Dallas, Texas, US.
- 2024. Emerging treatments in non muscle invasive bladder cancer. Conference. Aspen Urological Conference. Asoen, CO, US.
- 2023. Surgical management of node positive bladder cancer. Invited. URMC Urology 5th Annual Bladder Cancer Symposium. Rochester, NY, US.
- 2023. ”Robotic Radical Cystectomy and intracorporeal urinary diversions in Female patients- step by step”. Invited. Sao Paulo, BR.
- 2023. Optimal management of cN+ bladder cancer. Conference. Optimal management of cN+ bladder cancer. Chicago, IL, US.
- 2023. Three papers that influenced my practice. Conference. Three papers that influenced my practice. Chicago, IL, US.
- 2023. Bladder Cancer Cases. Conference. The University of Chicago. Aspen, CO, US.
- 2023. Telehealth in the Post Covid Era. Conference. The University of Chicago. Aspen, CO, US.
- 2023. Robotic Radical Cystectomy - Controversy and Evidence. Conference. The University of Chicago. Aspen, CO, US.
- 2023. Clinical Pearls - Node Positive Bladder Cancer. Conference. The University of Chicago. Aspen, CO, US.
- 2022. Telemedicine Presence at MDACC. Conference. UT MD Anderson Cancer Center. Steamboat Springs, CO, US.
- 2021. Speaker: Clinical N+ Disease: What is the Role of Surgical or Radiotherapy Consolidation vs. Check Maintenance Immunotherapy?. Conference. SUO Bladder Cancer Course. Orlando, FL, US.
International Presentations
- 2025. Thematic Session 'Rapid-fire debates: Common problems and controversies in bladder cancer. Panelist. European Association of Urology 2025. Barcelona, ES.
- 2023. Surgical management of node positive bladder cancer. Invited. TUA and MD Anderson International Uro-Oncological Conference. Taichung, TW.
- 2023. Robotic radical cystectomy - controversies and evidence. Visiting. Taiwan Urologic Association. Taipei, TW.
Formal Peers
- 2022. Innovations in Virtual Care. Invited. Houston, TX, US.
- 2021. Telemedicine in the Oncology Setting: A Panel Discussion. Invited. San Diego, CA, US.
- 2015. Advanced Robotic Surgery Workshop. Invited. Kuwait City, KW.
- 2014. Second Line Therapy for Non Muscle Invasive Bladder Cancer. Invited. Houston, TX, US.
- 2013. Active Surveillance for Prostate Cancer. Invited. Houston, TX, US.
Selected Publications
Peer-Reviewed Articles
- Soliman, C, Sathianathen, NJ, Corcoran, NM, Lawrentschuk, N, Wuethrich, PY, Furrer, MA, Ali, FA, Shah Bin Abd Karim, MF, Abouelenein, M, Ghanem, YA, Adam, A, Adami, A, Adamos, K, Adamou, C, Adeyeye, A, Aellen, F, Afferi, L, Agarwal, A, Agarwal, DK, Agarwal, V, Agostini, E, Agrawal, M, Agüera Sánchez, MÁ, Ahmad, S, Ahour, RT, Akbarov, I, Akbas, S, Akdogan, N, Aksaray, EE, Al-Bermani, O, Al-Monajjed, R, Al-Rammahi, D, Albala, DM, Albers, P, Albertsen, PC, Albuheissi, S, Ali, HA, Ibrahim Ali Mohsen, MA, Almarzouq, A, Altaylouni, T, Ambulkar, R, Bree, KK, Cata, JP, Dinney, CP, Gottumukkala, V, Haque, S, Lasala, J, Navai, N, Popat, KU, Shah, JB. The CAMUS Initiative. European Urology Open Science 87:57-70, 2026. e-Pub 2026. PMID: 42003843.
- Chapin BF, Smaldone M, Zurita AJ, Wang J, Cooperberg MR, Gleave M, Delacroix SE, Davis J, Pettaway C, Pisters L, Adibi M, Chery L, Papadopoulos J, Ward J, Gregg J, Navai N, Corn P, Subudhi SK, Logothetis C, Kuban D, Nguyen Q, Tang C, Choi S, Hoffman K, Lozano M, Elsheftawi M, Achim M, Zhao Y, Ramesh N, Sei E, Navin N, Nogueras Gonzalez GM, Wang X, Zhu K, Troncoso P, Zhang M, McGuire S, Aparicio AM. A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer. Eur Urol, 2026. e-Pub 2026. PMID: 41833492.
- Carriere P, Alhalabi O, Gao J, Shah A, Goswami S, Campbell M, Lin R, Mayo L, Mohamad O, Hoffman K, Mok H, Lozano C, Kamat A, Navai N, Bree K, Lee B, Guo C, Rooney M, Tang C, Choi S, Hassanzadeh C. Metastasis-directed radiotherapy for oligometastatic urothelial carcinoma of the bladder and upper tract. Bladder Cancer 12(1):23523735251414249, 2026. e-Pub 2026. PMID: 41550986.
- Lee, S, Jung, SY, Kuś, P, Bondaruk, J, Lee, JG, Jaksik, R, Putluri, N, Dinh, KN, Cogdell, D, Chen, H, Wang, Y, Chen, J, Navai, N, Dinney, CP, Mendelsohn, C, McConkey, DJ, Behringer, RR, Guo, CC, Wei, P, Kimmel, M, Czerniak, BA. Dysregulated mitochondrial energy metabolism drives the progression of mucosal field effects to invasive bladder cancer. Journal of Pathology 267(3):329-346, 2025. e-Pub 2025. PMID: 40996337.
- Carriere, P, Alhalabi, O, Gao, J, Mohamad, O, Campbell, M, Shah, AY, Goswami, S, Bree, KK, Lee, B, Navai, N, Mok, H, Mayo, LL, Guo, CC, Nguyen, Q, McGuire, SE, Park, R, Shah, SJ, Hoffman, K, Frank, SJ, Tang, C, Choi, S, Kamat, A, Hassanzadeh, CJ. Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer. Clinical and Translational Radiation Oncology 49, 2024. e-Pub 2024. PMID: 39403573.
- Carriere P, Alhalabi O, Gao J, Mohamad O, Campbell MT, Shah A, Goswami S, Bree K, Lee B, Navai N, Mok H, Mayo L, Guo C, Nguyen Q, McGuire S, Park R, Shah S, Hoffman K, Frank S, Tang C, Choi S, Kamat A, Hassanzadeh C. Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer. Clin Transl Radiat Oncol 49:100866, 2024. e-Pub 2024. PMID: 39403573.
- Campbell MT, Shah AY, Msaouel P, Tannir NM, Siefker-Radtke AO, Kamat AM, Navai N, Dinney CPN, Rao P, Guo CC, Sheth RA, Venkatesan AM, Tidwell RS, Yadav SS, Gu A, Chen H, Macaluso M, Duan F, Basu S, Jindal S, Sharma P. A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer. Cancer Res Commun 4(9):2444-2453, 2024. e-Pub 2024. PMID: 39207194.
- Contieri, R, Tan, WS, Grajales, V, Hensley, PJ, Martini, A, Bree, KK, Myers, AA, Nogueras Gonzalez, G, Navai, N, Dinney, CP, Guo, CC, Kamat, A. Influence of lamina propria invasion extension on T1 high-grade non-muscle-invasive bladder cancer in patients undergoing BCG or radical cystectomy. BJU International 133(6):733-741, 2024. e-Pub 2024. PMID: 38374533.
- Lee, S, Bondaruk, J, Wang, Y, Chen, H, Lee, JG, Majewski, T, Mullen, RD, Cogdell, D, Chen, J, Wang, Z, Yao, H, Kuś, P, Jeong, J, Lee, I, Choi, W, Navai, N, Guo, C, Dinney, CP, Baggerly, KA, Mendelsohn, C, McConkey, D, Behringer, RR, Kimmel, M, Wei, P, Czerniak, BA. Loss of LPAR6 and CAB39L dysregulates the basal-to-luminal urothelial differentiation program, contributing to bladder carcinogenesis. Cell Reports 43(5), 2024. e-Pub 2024. PMID: 38676926.
- Sood, A, Rudzinski, JK, Labbate, CV, Hensley, PJ, Bree, KK, Guo, CC, Alhalabi, O, Campbell, M, Siefker-Radtke, AO, Navai, N, Dinney, CP, Gao, J, Kamat, A. Long-Term Oncological Outcomes in Patients Diagnosed With Nonmetastatic Plasmacytoid Variant of Bladder Cancer. Journal of Urology 211(2):241-255, 2024. e-Pub 2024. PMID: 37922370.
- Contieri, R, Grajales, V, Tan, WS, Martini, A, Sood, A, Hensley, PJ, Bree, KK, Lobo, N, Nogueras Gonzalez, G, Guo, CC, Navai, N, Dinney, CP, Kamat, A. Impact of age >70 years on oncological outcomes in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette–Guérin. BJU International 133(1):63-70, 2024. e-Pub 2024. PMID: 37442564.
- Moussa, MJ, Chen, AH, Grana, AK, Gao, J, Shah, AY, Corn, P, Tannir, NM, Goswami, S, Wang, J, Araujo, JC, Kamat, A, Navai, N, Pettaway, CA, Adibi, M, Czerniak, BA, Guo, CC, Siefker-Radtke, AO, Campbell, M, Alhalabi, O. Clinical outcomes of frontline GemFLP in advanced urachal and non-urachal adenocarcinomas of the urinary tract. Journal of Clinical Oncology 42(4), 2024. e-Pub 2024.
- Contieri, R, Hensley, PJ, Tan, WS, Grajales, V, Bree, KK, Nogueras Gonzalez, G, Lee, B, Navai, N, Dinney, CP, Kamat, A. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. European Urology Oncology 6(6):590-596, 2023. e-Pub 2023. PMID: 37558542.
- Alhalabi, O, Wilson, NR, Xiao, L, Lin, Y, Khandelwal, J, Moussa, MJ, Msaouel, P, Navai, N, Gao, J, Kamat, A, Pilie, PG, Shah, AY, Goswami, S, Matin, S, Kovitz, CA, Holla, V, Guo, C, Czerniak, BA, Logothetis, CJ, Corn, P, Dinney, CP, Campbell, M, Hansel, DE, Tannir, NM, Siefker-Radtke, AO. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. European Urology Oncology 6(6):611-620, 2023. e-Pub 2023. PMID: 37833193.
- Tan, WS, McElree, IM, Davaro, F, Steinberg, RL, Bree, KK, Navai, N, Dinney, CP, O'Donnell, M, Li, R, Kamat, A, Packiam, V. Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. European Urology Oncology 6(5):531-534, 2023. e-Pub 2023. PMID: 37468392.
- Tan, WS, Grajales, V, Contieri, R, Hensley, PJ, Bree, KK, Msaouel, P, Guo, CC, Nogueras Gonzalez, G, Navai, N, Dinney, CP, Kamat, A. Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin–unresponsive Non–muscle-invasive Bladder Cancer. European Urology Open Science 53:16-22, 2023. e-Pub 2023. PMID: 37441349.
- Wang, XS, Bree, KK, Navai, N, Jomaa, M, Shen, SE, Letona, E, Cleeland, C, Shi, Q, Gottumukkala, V. Utility of Patient-Reported Symptom and Functional Outcomes to Indicate Recovery after First 90 Days of Radical Cystectomy. Cancers 15(11), 2023. e-Pub 2023. PMID: 37297013.
- Hensley, PJ, Duan, Z, Bree, KK, Sood, A, Zhao, H, Lobo, N, Contieri, R, Campbell, M, Guo, CC, Navai, N, Williams, SB, Dinney, CP, Kamat, A. Competing mortality risk from second primary malignancy in bladder cancer patients following radical cystectomy. Urologic Oncology: Seminars and Original Investigations 41(2):108.e11-108.e17, 2023. e-Pub 2023. PMID: 36404232.
- Bree, KK, Kokorovic, A, Westerman, ME, Hensley, PJ, Brooks, NA, Qiao, W, Shen, Y, Kamat, A, Dinney, CP, Navai, N. Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy is Prognostic but Not Therapeutic. Journal of Urology 209(1):140-149, 2023. e-Pub 2023. PMID: 36250944.
- Westerman, ME, Bree, KK, Msaouel, P, Kukreja, JB, Mantaring, C, Rukundo, I, Gonzalez, MG, Gregg, JR, Casteel, KN, Matin, S, Lafleur, AD, Best, RN, Crump, LD, Cunningham, JM, Saucedo, MA, Valle, DD, Varghese, R, Adibi, M, Chapin, BF, Chery, LJ, Davis, JW, Dinney, CP, Graber, WJ, Kamat, A, Karam, JA, Navai, N, Papadopoulos, JN, Pettaway, CA, Pisters, LL, Smith III, T, Ward, JF, Westney, OL, Wood, CG. Apixaban vs Enoxaparin for Post-Surgical Extended-Duration Venous Thromboembolic Event Prophylaxis. Journal of Urology 208(4):886-895, 2022. e-Pub 2022. PMID: 36082549.
- Lobo, N, Hensley, PJ, Bree, KK, Nogueras Gonzalez, G, Navai, N, Dinney, CP, Kamat, A. Should patients with non-muscle-invasive bladder cancer discontinue fibrin clot inhibitors during bacille Calmette–Guérin?. BJU International 130(4):463-469, 2022. e-Pub 2022. PMID: 34854189.
- Labbate, CV, Hensley, PJ, Miest, T, Qiao, W, Adibi, M, Shah, AY, Chery, LJ, Papadopoulos, JN, Siefker-Radtke, AO, Gao, J, Guo, CC, Czerniak, BA, Navai, N, Kamat, A, Dinney, CP, Campbell, M, Matin, S. Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations 40(10):454.e17-454.e23, 2022. e-Pub 2022. PMID: 35961847.
- Lobo, N, Bree, KK, Hensley, PJ, Nogueras Gonzalez, G, Abraham, P, Navai, N, Dinney, CP, Kamat, A. Reduced-dose bacillus Calmette-Guérin (BCG) in an era of BCG shortage. BJU International 130(3):323-330, 2022. e-Pub 2022. PMID: 34847263.
- Bree, KK, Hensley, PJ, Lobo, N, Brooks, NA, Nogueras Gonzalez, G, Guo, CC, Navai, N, Barton Grossman, H, Dinney, CP, Kamat, A. All High-Grade Ta Tumors Should Be Classified as High Risk. Journal of Urology 208(2):284-291, 2022. e-Pub 2022. PMID: 35770498.
- Jomaa, M, Navai, N, Bree, KK, Williams, LA, Cleeland, C, Shen, SE, Wang, XS. Validation and Application of MD Anderson Symptom Inventory Module for Patients with Bladder Cancer in the Perioperative Setting. Cancers 14(16), 2022. e-Pub 2022. PMID: 36010890.
- Bondaruk, J, Jaksik, R, Wang, Z, Cogdell, D, Lee, S, Chen, Y, Dinh, KN, Majewski, T, Zhang, L, Cao, S, Tian, F, Yao, H, Kuś, P, Chen, H, Weinstein, JN, Navai, N, Dinney, CP, Gao, J, Theodorescu, D, Logothetis, CJ, Guo, CC, Wang, W, McConkey, DJ, Wei, P, Kimmel, M, Czerniak, BA. The origin of bladder cancer from mucosal field effects. iScience 25(7), 2022. e-Pub 2022. PMID: 35747385.
- Hensley, PJ, Bree, KK, Brooks, NA, Matulay, JT, Li, R, Nogueras Gonzalez, G, Nagaraju, S, Navai, N, Barton Grossman, H, Dinney, CP, Kamat, A. Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes. European Urology Oncology 5(3):347-356, 2022. e-Pub 2022. PMID: 33935020.
- Adibi, M, McCormick, B, Economides, MP, Petros, FG, Xiao, L, Guo, CC, Shah, AY, Kamat, A, Dinney, CP, Navai, N, Gao, J, Siefker-Radtke, AO, Matin, S, Campbell, M. Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma. Clinical Genitourinary Cancer 20(2):176-182, 2022. e-Pub 2022. PMID: 35039231.
- Khanna, A, Miest, T, Sharma, V, Campbell, R, Hensley, PJ, Thapa, P, Zganjar, A, Tollefson, MK, Thompson, RH, Frank, I, Karnes, RJ, Murthy, PB, Haber, GP, Navai, N, Kamat, A, Dinney, CP, Lee, B, Boorjian, SA. Role of Lymphadenectomy during Radical Cystectomy for Nonmuscle-Invasive Bladder Cancer. Journal of Urology 207(3):551-558, 2022. e-Pub 2022. PMID: 34694143.
- Lobo, N, Hensley, PJ, Bree, KK, Nogueras Gonzalez, G, Navai, N, Dinney, CP, Sylvester, R, Kamat, A. Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin. European Urology Oncology 5(1):84-91, 2022. e-Pub 2022. PMID: 34920986.
- Sood, A, Keeley, J, Palma-Zamora, I, Novara, G, Elshaikh, M, Jeong, W, Hensley, PJ, Navai, N, Peabody, JO, Trinh, QD, Rogers, CG, Menon, M, Abdollah, F. High-intensity local treatment of clinical node-positive urothelial carcinoma of the bladder alongside systemic chemotherapy improves overall survival. Urologic Oncology: Seminars and Original Investigations 40(2):62.e1-62.e11, 2022. e-Pub 2022. PMID: 34348860.
- Alhalabi, O, Campbell, M, Xiao, L, Adriazola, AC, Wilson, NR, Siefker-Radtke, AO, Corn, P, Zurita-Saavedra, A, Jonasch, E, Gao, J, Adibi, M, Kamat, A, Navai, N, Pisters, LL, Dinney, CP, Matin, S, Shah, AY. Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma. BJUI Compass 3(1):37-44, 2022. e-Pub 2022. PMID: 35475152.
- Hensley, PJ, Bree, KK, Brooks, NA, Matulay, JT, Li, R, Nogueras Gonzalez, G, Navai, N, Barton Grossman, H, Dinney, CP, Kamat, A. Time interval from transurethral resection of bladder tumour to bacille Calmette–Guérin induction does not impact therapeutic response. BJU International 128(5):634-641, 2021. e-Pub 2021. PMID: 33783950.
- Westerman, ME, Bree, KK, Kokorovic, A, Frank, J, Wang, XS, Kamat, A, Dinney, CP, Navai, N. What Women Want. Urology 157:181-187, 2021. e-Pub 2021. PMID: 34186127.
- Bree, KK, Hensley, PJ, Brooks, NA, Matulay, JT, Li, R, Nogueras Gonzalez, G, Navai, N, Barton Grossman, H, Matin, S, Dinney, CP, Kamat, A. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer. BJU International 128(5):568-574, 2021. e-Pub 2021. PMID: 33484074.
- Hensley, PJ, Bree, KK, Campbell, M, Alhalabi, O, Kokorovic, A, Miest, T, Nogueras Gonzalez, G, Gao, J, Siefker-Radtke, AO, Guo, CC, Navai, N, Dinney, CP, Kamat, A. Reply by Authors. The Journal of Urology 206(5):1267, 2021. e-Pub 2021. PMID: 34372685.
- Bree, KK, Hensley, PJ, Brooks, NA, Matulay, JT, Nogueras Gonzalez, G, Navai, N, Dinney, CP, Kamat, A. Impact of sex on response to BCG in non-muscle invasive bladder cancer patients. World journal of urology 39(11):4143-4149, 2021. e-Pub 2021. PMID: 34117914.
- Hensley, PJ, Bree, KK, Campbell, M, Alhalabi, O, Kokorovic, A, Miest, T, Nogueras Gonzalez, G, Gao, J, Siefker-Radtke, AO, Guo, CC, Navai, N, Dinney, CP, Kamat, A. Progression of Disease after Bacillus Calmette-Guérin Therapy. Journal of Urology 206(5):1258-1266, 2021. e-Pub 2021. PMID: 34184926.
- Bree, KK, Hensley, PJ, Westerman, ME, Kokorovic, A, Nogueras Gonzalez, G, Dinney, CP, Kamat, A, Navai, N. Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer. Journal of Urology 206(3):577-585, 2021. e-Pub 2021. PMID: 33872050.
- Kukreja, JB, Li, R, Narayan, VM, Lim, A, Seif, MA, Wang, X, Kamat, A, Dinney, CP, Navai, N. Oncologic Equipoise between Robotic and Open Radical Cystectomy. Journal of Endourology 35(8):1168-1176, 2021. e-Pub 2021. PMID: 33619985.
- Brooks, NA, Kokorovic, A, Xiao, L, Matulay, JT, Li, R, Ranasinghe, WK, Nagaraju, S, Shen, Y, Gao, J, Navai, N, Dinney, CP, Barton Grossman, H, Kamat, A. The obesity paradox. BJU International 128(1):65-71, 2021. e-Pub 2021. PMID: 33210440.
- Matulay, JT, Li, R, Hensley, PJ, Brooks, NA, Narayan, VM, Barton Grossman, H, Navai, N, Dinney, CP, Kamat, A. Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guérin. Journal of Urology 205(6):1612-1619, 2021. e-Pub 2021. PMID: 33502236.
- Kukreja, JB, Seif, MA, Mery, MW, Incalcaterra, JR, Kamat, A, Dinney, CP, Shah, JB, Feeley, TW, Navai, N. Utilizing time-driven activity-based costing to determine open radical cystectomy and ileal conduit surgical episode cost drivers. Urologic Oncology: Seminars and Original Investigations 39(4):237.e1-237.e5, 2021. e-Pub 2021. PMID: 33308972.
- Millward, NZ, Wang, L, Maity, T, Li, L, Millward, S, Karam, JA, Wood, CG, Navai, N. Prolyl hydroxylase 3 knockdown accelerates VHL-mutant kidney cancer growth in vivo. International journal of molecular sciences 22(6):1-16, 2021. e-Pub 2021. PMID: 33799686.
- Kokorovic, A, Westerman, ME, Krause, KJ, Hernandez, M, Brooks, NA, Dinney, CP, Kamat, A, Navai, N. Revisiting an Old Conundrum. Bladder Cancer 7(2):243-252, 2021. e-Pub 2021. PMID: 34195319.
- Mmeje, CO, Guo, CC, Shah, JB, Navai, N, Barton Grossman, H, Dinney, CP, Kamat, A. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy. European urology 70(5):778-785. PMID: 26922408.
- Metcalfe, MJ, Ferguson, JE, Li, R, Xiao, L, Guo, CC, Czerniak, BA, Siefker-Radtke, AO, Pretzsch, SM, Navai, N, McConkey, DJ, Kamat, A, Campbell, M, Dinney, CP. Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. European Urology Focus 3(6):577-583. PMID: 28753816.
Review Articles
- Gupta S, Hensley PJ, Li R, Choudhury A, Daneshmand S, Faltas BM, Flaig TW, Grass GD, Grivas P, Hansel DE, Hassanzadeh C, Kassouf W, Kukreja J, Mendoza-Valdes A, Moschini M, Mouw KW, Navai N, Necchi A, Rosenberg JE, Ross JS, Siefker-Radtke AO, Taylor J, Willliams SB, Zlotta AR, Buckley R, Kamat AM. Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group. Eur Urol 89(1):18-28, 2025. e-Pub 2025. PMID: 40268594.
- Cohen, AB, Stump, L, Krumholz, HM, Cartiera, M, Jain, S, Scott Sussman, L, Hsiao, A, Lindop, W, Ying, AK, Kaul, RL, Balcezak, TJ, Tereffe, W, Comerford, M, Jacoby, D, Navai, N. Aligning mission to digital health strategy in academic medical centers. npj Digital Medicine 5(1), 2022. e-Pub 2022. PMID: 35654885.
- Lim, A, Westerman, ME, Korokovic, A, Matulay, JT, Narayan, VM, Navai, N. Efficacy of Surgery on the Primary Tumour in Patients with Metastatic Bladder Cancer. Bladder Cancer 8(2):193-209, 2022. e-Pub 2022. PMID: 38993364.
Other Articles
- Tan, WS, Grajales, V, Bree, KK, Li, R, Nogueras Gonzalez, G, Navai, N, Dinney, CP, Kamat, A Bacillus Calmette–Guérin (BCG) unresponsive non-muscle-invasive bladder cancer. BJU International 132(4):384-386, 2023. PMID: 37246493.
- Bondaruk, J, Jaksik, R, Wang, Z, Cogdell, D, Lee, S, Chen, Y, Dinh, KN, Majewski, T, Zhang, L, Cao, S, Tian, F, Yao, H, Kuś, P, Chen, H, Weinstein, JN, Navai, N, Dinney, CP, Gao, J, Theodorescu, D, Logothetis, CJ, Guo, CC, Wang, W, McConkey, DJ, Wei, P, Kimmel, M, Czerniak, BA Erratum. iScience 25(7), 2022. PMID: 35811851.
- Matulay, JT, Li, R, Hensley, PJ, Brooks, NA, Narayan, VM, Barton Grossman, H, Navai, N, Dinney, CP, Kamat, A Reply by Authors. Journal of Urology 205(6):1620-1621, 2021. PMID: 33734859.
Abstracts
- Sood A, Lim A. Pathologic Downstaging Rate and Predictive Biomarker Exploration in Patients with Biopsy-Proven Clinically Node Positive Bladder Cancer Undergoing Chemotherapy Followed by Radical Cystectomy, 2023. e-Pub 2023.
- M Kamat ASJKRCVLPJHKKBCCGOAMTCAOSNNCPDJGA. LONG-TERM ONCOLOGICAL OUTCOMES IN PATIENTS DIAGNOSED WITH NON-METASTATIC PLASMACYTOID VARIANT OF BLADDER CANCER: A 20-YEAR UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER EXPERIENCE, 2022. e-Pub 2022.
- N Dinney APMSMNNAMKDJMCP. GENERATION AND VALIDATION OF A PREDICTIVE URINE-MICRORNA SIGNATURE FOR INTRAVESICAL BCG THERAPY, 2022. e-Pub 2022.
- Hensley P, Lobo N, Bree K, Sood A, Navai N, Dinney C, Kamat AA. TIMING OF RADICAL CYSTECTOMY FOR BCG FAILURE. The Journal of Urology, 2022. e-Pub 2022.
- Bree KK, Hensley PJ, Brooks NA, Nogueras-Gonzalez GM, Navai N, Grossman HB, Dinney CP, Kamat AM. All HG NMIBC is high risk: BCG response in HG Ta lesions. Eur Urol 79,(1S, Supplement):S990-S991. e-Pub 2021.
- Hensley, PJ, Miest, T, Adibi, M, Campbell, M, Shah, A, Cherry, L, Papadopoulos, J, Siefker-Radtke, A, Gao, J, Guo, C, Czerniak, B, Navai N, Kamat, A, Dinney, C, Matin, S. GFR fluctuation induced by neoadjuvant chemotherapy correlates with pathologic stage of upper tract urothelial carcinoma. Eur Uro 79(S1, Supplement):S1090-S1091. e-Pub 2021.
- Alhalabi O, Wilson N, Navai N, Campbell MT, Shah AY, Gao J, Corn PG, Aparicio A, Czerniak B, Guo C, Logothetis C, Tannir NM, Choi S, Siefker-Radtke AO. Survival outcomes in patients receiving immune checkpoint inhibitor (ICI) for metastatic small cell urothelial cancer (SCUC). Journal of Clinical Oncology 39:4543-4543, 2021. e-Pub 2021.
Book Chapters
- Narayan, VM, Navai, N. Robot-assisted radical cystectomy, 1159-1164, 2021.
Letters to the Editor
- Myers, AA, Tan, WS, Grajales, V, Hwang, H, Bree, KK, Navai, N, Lee, B, Dinney, CP, Kamat, A. Challenging the Paradigm of “BCG-unresponsive” Bladder Cancer. European urology 86: 366-368, 2024.
- Bree, KK, Navai, N. Repeat Transurethral Resection of Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply. Journal of Urology 210: 839, 2023.
- Bree K, Navai N. Repeat Transurethral Resection of Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply. J Urol 210: 839-840, 2023.
- Bree, KK, Kokorovic, A, Westerman, ME, Hensley, PJ, Brooks, NA, Qiao, W, Shen, Y, Kamat, A, Dinney, CP, Navai, N. Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply. Journal of Urology 210: 254-255, 2023.
- Bree, KK, Hensley, PJ, Lobo, N, Brooks, NA, Nogueras Gonzalez, G, Guo, CC, Navai, N, Barton Grossman, H, Dinney, CP, Kamat, A. Reply by Authors. Journal of Urology 208: 290-291, 2022.
- Bree, KK, Navai, N. Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer. Journal of Urology 207: 477, 2022.
Patient Reviews
CV information above last modified August 05, 2026